DCE-MRI Study Abstract Selected by ASCO

May 26, 2010
Company News Release

ACR Image Metrix

™ is pleased to announce that the DCE-MRI study, as commissioned by

Bionomics Ltd.

, was submitted as an abstract by Bionomics to the American Society of Clinical Oncology (ASCO) and has been accepted to be presented as a part of the scientific program during the general poster session at the

ASCO Annual Meeting

, which will take place June 4-8, 2010, in Chicago, Illinois, at McCormick Place.

As a drug discovery and development organization focusing on new treatments for cancer and serious disorders of the central nervous system, Bionomics selected ACR Image Metrix to perform the imaging components of this study.  

“Their extensive experience in the utilization of novel imaging techniques to serve as biomarkers and history of partnering with regulatory agencies to develop standards for imaging acquisition, data normalization, data extraction and the assessment of variability made the selection of ACR Image Metrix as our imaging CRO appropriate for this project,” stated Bionomics Vice President of Discovery Research, Gabriel Kremmidiotis, Ph.D.

The completion of this Phase I clinical trial, which involved

MRI (DCE-MRI)

 quantitative analysis, was a two-stage dose escalation design involving Bionomics’ BNC 105P-001, a novel vascular disrupting agent staged in patients with advanced solid tumors.

“Teaming up with Bionomics to complete this study turned out to be a success and we are pleased with the results. This is a major milestone for ACR Image Metrix in our ability to conduct novel imaging for both pharmaceutical and biotech companies,” stated General Manager of ACR Image Metrix, Michael J. Morales.

ACR Image Metrix will also be exhibiting at the ASCO Annual Meeting, Booth 19097.